• Progress on Gavi 4.0
• Covid-19 response and risks
• Implications for Gavi 5.0
• Decisions

Anuradha Gupta – 24 June 2020, Geneva
2019 was a record year of performance, building further momentum on Gavi 4.0

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine introductions</td>
<td>45</td>
<td>35</td>
<td>46</td>
<td>59</td>
<td>185 introductions</td>
</tr>
<tr>
<td>HSS disbursements (in $m)</td>
<td>$194</td>
<td>$226</td>
<td>$294</td>
<td>$331</td>
<td>&gt;$1bn disbursed in HSS</td>
</tr>
<tr>
<td>Timely Co-financing¹</td>
<td>94%</td>
<td>92%</td>
<td>94%</td>
<td>98%</td>
<td>$1.25bn financed by countries</td>
</tr>
<tr>
<td>Vaccine prices²</td>
<td>$19</td>
<td>$16.63</td>
<td>$15.90</td>
<td>$15.57</td>
<td>&gt;22% reduction in prices</td>
</tr>
</tbody>
</table>

1 Share of countries meeting co-financing commitments on time; total amounts co-financed and self-financed by countries including India
2 Cost of fully vaccinating a child with pentavalent, rotavirus and pneumococcal conjugate vaccine (PCV)
In 2020, Covid-19 is setting us back amid unprecedented uncertainty

In Gavi countries:

- Sharp increase in Covid-19 cases
- Countries in a state of flux
- Massive economic and fiscal impact
- Immunisation most disrupted among essential health services
- Inequities exacerbated

Imminent risks:

- Stress on domestic financing for vaccines and service delivery
- Drop in coverage
- Increased outbreaks
- More zero-dose children
- More child deaths in poor households
Gavi acted swiftly to help countries in their immediate response to the pandemic

- Reprogramming of HSS up to 10%
- Repurposing of partners’ support under PEF TCA
- Freezing of eligibility status and co-financing at 2020 level
- Fast-tracked approvals
- Regular dialogue and information sharing across the Alliance

- $76m of support approved in 43 countries
- 54% used for IPC and PPE
- Procurement of PPE through UNICEF
- Alignment with national Covid-19 plans
- Coordination with other financiers
Maintaining and restoring immunisation now a priority: Opportunity to rebuild better

- Enhanced focus on equity and gender in immunisation
- Catching up missed children through tailored, integrated, efficient approaches
- Tackling growing vaccine hesitancy and rumors
- Re-imagining surveillance
- Promoting innovation
- Broadening partnerships
While Gavi 5.0 is more relevant than ever, a few priorities and baseline would shift.

Baseline and targets contingent on pandemic duration and scale of disruption

Equitable access and delivery of Covid 19 vaccines

Deferring VIS implementation

Recalibrating expectations on domestic financing for immunisation and sustained performance in former Gavi countries
Covid-19 has impacted timelines of Funding Policy Review

- **Funding Policy review** paused on recommendation of Steering Committee

- Recognition of the **changing context** and **limited country capacity** to implement new policies

- Proposal to **roll-out only select funding policy shifts** already approved by the Board in December 2019

- **Policy review to resume** when countries are preparing to move to a steadier state: Board to be updated in December 2020
Gavi’s approach to MICs being adapted in the light of Covid-19

• Comprehensive approach to MICs paused because of Covid-19

• Former Gavi countries face increased risk of backsliding
  o current post-transition engagement is till 2020 only, limited to TA

• Proposal to allocate up to $20m for former Gavi countries in 2020-2021
  o excludes vaccines but goes beyond TA

• Covax offers opportunity to engage with never Gavi-eligible MICs and lay the foundation for broader engagement
Discussion topics:
- Progress on Gavi 4.0
- Covid-19 response and risks
- Implications for Gavi 5.0
- Decisions
THANK YOU